Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

Biedenbach, Douglas J.; Bouchillon, S.; Hackel, Meredith; Hoban, Daryl J.; Kazmierczak, Krystyna M.; Hawser, Stephen; Badal, R.

doi:10.1128/aac.03938-14

Cited by 53 publications

(39 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple MBL-positive isolates were detected in Russia and Greece, and the prevalence and spread of MBL-positive organisms within and from these countries have been reported previously (18,(26)(27)(28). In this study, the large number of MBL-positive organisms isolated in Philippines, which included 5 different species of Enterobacteriaceae and P. aeruginosa carrying genes for all three MBL types, exceeded those in previous reports and might suggest a strong potential for further spread in diverse geographic regions (29,30). Some variants were detected in one or several species of Enterobacteriaceae, whereas others were found in both Enterobacteriaceae and P. aeruginosa isolates, suggesting that these variants were encoded on mobilizable elements with large host ranges.…”

Section: Discussionmentioning

confidence: 43%

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

Kazmierczak¹,

Rabine²,

Hackel³

et al. 2016

Antimicrob Agents Chemother

189

117

View full text Add to dashboard Cite

T he worldwide dissemination of Gram-negative bacteria producing extended-spectrum ␤-lactamases (ESBLs) in the late 20th century resulted in a dearth of treatment options and an increase in the therapeutic use of carbapenems (1, 2). In turn, reports of carbapenem-resistant and carbapenemase-producing bacteria became more frequent (3-5). One important group of carbapenemases of special concern is the metallo-␤-lactamases (MBLs). These enzymes belong to Ambler class B and require 1 or 2 zinc ions for enzyme activity (6). Many MBLs are chromosomally encoded in environmental bacteria or species that can act as opportunistic pathogens. However, a number of MBLs, including the NDM-type, IMP-type, and VIM-type MBLs, are plasmid encoded and readily transferable among clinically significant bacterial species, including Klebsiella pneumoniae and Escherichia coli (3). Notably, MBLs are often coproduced with Ambler class A and C serine ␤-lactamases, including ESBLs and AmpC enzymes (7).MBLs hydrolyze all ␤-lactams except monobactams, including aztreonam, and are not inhibited by any of the commercially available ␤-lactamase inhibitors. Although aztreonam is active against many Gram-negative bacteria, it is inactive against isolates that produce ESBLs, KPC carbapenemases, or plasmid-encoded or stably derepressed, chromosomally encoded AmpC ␤-lactamases, thereby limiting its potential utility against MBL-producing isolates that also contain one or more of these serine ␤-lactamases (8). Avibactam is a non-␤-lactam ␤-lactamase inhibitor that is active against Ambler class A and C and some class D (OXA-48) enzymes (9, 10). Aztreonam combined with avibactam has demonstrated activity against Enterobacteriaceae that coproduce MBLs and class A or class C ␤-lactamases (11, 12).As part of a global surveillance program, the molecular basis of carbapenem resistance in Gram-negative pathogens was investigated in order to determine the incidence of acquired MBLs and the geographic regions in which these ␤-lactamases are most problematic. This report describes the isolation and regional distribution of MBL-positive Enterobacteriaceae and Pseudomonas aeruginosa isolates collected from 2012 to 2014. MATERIALS AND METHODSNonduplicate bacterial isolates from intra-abdominal, urinary tract, skin and soft tissue, lower respiratory tract, and bloodstream infections were collected from 202 sites in 40 countries located in five major geographic regions (Asia-Pacific, Europe, Latin America, the Middle East-Africa, and North America). A predefined number of isolates of selected bacterial species were collected from each site regardless of antibiotic susceptibility. Organism collection, transport, confirmation of organism identification, susceptibility testing, molecular characterization, quality assurance of

show abstract

Section: Discussionmentioning

confidence: 43%

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

Kazmierczak¹,

Rabine²,

Hackel³

et al. 2016

Antimicrob Agents Chemother

189

117

View full text Add to dashboard Cite

show abstract

“…Isolates from mainland China (all years) and India (most isolates from 2010 and all isolates from 2011 to 2014) were excluded from all aspects of this study because they were not available for molecular characterization due to export restrictions. Specific isolate collection protocols for the SMART program have been described previously (29). All isolates in this study were shipped to International Health Management Associates, Inc. (IHMA, Schaumburg, IL, USA), where their identities were confirmed using RapID One or NF Plus biochemical systems (Remel, Lenexa, KS) (isolates collected in 2008 to 2011) or a Bruker Biotyper matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) spectrometry instrument (Bruker Daltonics, Billerica, MA, USA) (isolates collected in 2012 to 2014), and reference antimicrobial susceptibility testing (11,30) Per SMART program protocol, all ertapenem-nonsusceptible isolates of Enterobacteriaceae as well as a random selection of 50% of E. coli, K. pneumoniae, K. oxytoca, and P. mirabilis isolates positive for ESBL activity by combination clavulanic acid testing (i.e., phenotypically ESBL positive) were to be characterized molecularly.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014

Karlowsky

Lob²,

Kazmierczak³

et al. 2017

J Clin Microbiol

View full text Add to dashboard Cite

The Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program collected 103,960 isolates of Enterobacteriaceae from 2008 to 2014. From this isolate collection, all ertapenem-nonsusceptible isolates (MIC, Ն1 g/ml; n ϭ 3,428) and 9,371 isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and Proteus mirabilis with an ertapenem-susceptible extended-spectrum-␤-lactamase (ESBL)-positive phenotype were assessed for the presence of common carbapenemase genes using a Check-MDR CT101 microarray (Check-Points,

show abstract

“…Carbapenem resistance rates are high among Gram-negative bacteria in the hospitals of South and Southeast Asia (4)(5)(6)(7)(8)(9)(10)(11), especially in Acinetobacter baumanniicalcoaceticus complex (AB) isolates (5,(7)(8)(9). South Asia is probably the source of the New Delhi metallo-␤-lactamase-1 (NDM-1) gene, which encodes one of the most widely distributed carbapenemases in terms of geographic spread and bacterial species (6), although virtually all other carbapenemase genes have been described in Enterobacteriaceae and nonfermenting Gram-negative bacteria from hospitals in both South and Southeast Asian countries (5,(7)(8)(9)(10)(11)(12)(13).…”

Section: Introduction Cmentioning

confidence: 99%

Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia

et al. 2017

View full text Add to dashboard Cite

SUMMARY Carbapenem-resistant Gram-negative bacteria, in particular the Acinetobacter baumannii-calcoaceticus complex and Enterobacteriaceae, are escalating global public health threats. We review the epidemiology and prevalence of these carbapenem-resistant Gram-negative bacteria among countries in South and Southeast Asia, where the rates of resistance are some of the highest in the world. These countries house more than a third of the world's population, and several are also major medical tourism destinations. There are significant data gaps, and the almost universal lack of comprehensive surveillance programs that include molecular epidemiologic testing has made it difficult to understand the origins and extent of the problem in depth. A complex combination of factors such as inappropriate prescription of antibiotics, overstretched health systems, and international travel (including the phenomenon of medical tourism) probably led to the rapid rise and spread of these bacteria in hospitals in South and Southeast Asia. In India, Pakistan, and Vietnam, carbapenem-resistant Enterobacteriaceae have also been found in the environment and community, likely as a consequence of poor environmental hygiene and sanitation. Considerable political will and effort, including from countries outside these regions, are vital in order to reduce the prevalence of such bacteria in South and Southeast Asia and prevent their global spread.

show abstract

Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

Cited by 53 publications

References 21 publications

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014

Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia

Contact Info

Product

Resources

About